Establishment and Validation of a Novel Disulfidptosis-related Immune Checkpoint Gene Signature in Clear Cell Renal Cell Carcinoma

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Jun 21

PMID 38904744

Authors

Lihuan Du

Nan Zhang

Bohan Wang

Wei Cheng

Jiaming Wen

Affiliations

Soon will be listed here.

Abstract

Background: Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of renal tumors and is associated with a unfavorable prognosis. Disulfidptosis is a recently identified form of cell death mediated by disulfide bonds. Numerous studies have highlighted the significance of immune checkpoint genes (ICGs) in ccRCC. Nevertheless, the involvement of disulfidptosis-related immune checkpoint genes (DRICGs) in ccRCC remains poorly understood.

Methods: The mRNA expression profiles and clinicopathological data of ccRCC patients were obtained from The Cancer Genome Atlas and Gene Expression Omnibus (GEO) databases. The associations between disulfidptosis-related genes (DRGs) and immune checkpoint genes (ICGs) were assessed to identify DRICGs. Cox regression analysis and least absolute shrinkage and selection operator (LASSO) analysis were conducted to construct a risk signature.

Results: A total of 39 differentially expressed immune-related candidate genes were identified. A prognostic signature was constructed utilizing nine DRICGs (CD276, CD80, CD86, HLA-E, LAG3, PDCD1LG2, PVR, TIGIT, and TNFRSF4) and validated using GEO data. The risk model functioned as an independent prognostic indicator for ccRCC, while the associated nomogram provided a reliable scoring system for ccRCC. Gene set enrichment analysis indicated enrichment of phospholipase D, antigen processing and presentation, and ascorbate and aldarate metabolism-related signaling pathways in the high-risk group. Furthermore, the DRICGs exhibited correlations with the infiltration of various immune cells. It is noteworthy that patients with ccRCC categorized into distinct risk groups based on this model displayed varying sensitivities to potential therapeutic agents.

Conclusions: The novel DRICG-based risk signature is a reliable indicator for the prognosis of ccRCC patients. Moreover, it also aids in drug selection and correlates with the tumour immune microenvironment in ccRCC.

References

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

Lucarelli G, Rutigliano M, Loizzo D, di Meo N, Lasorsa F, Mastropasqua M . MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome. Int J Mol Sci. 2022; 23(22). PMC: 9696833. DOI: 10.3390/ijms232213968. View

Okita K, Hatakeyama S, Tanaka T, Ikehata Y, Tanaka T, Fujita N . Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer. 2019; 17(3):e440-e446. DOI: 10.1016/j.clgc.2019.01.006. View

Hu F, Liu C, Liu L, Zhang Q, Guo A . Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Brief Bioinform. 2020; 22(3). DOI: 10.1093/bib/bbaa176. View

Lucarelli G, Netti G, Rutigliano M, Lasorsa F, Loizzo D, Milella M . MUC1 Expression Affects the Immunoflogosis in Renal Cell Carcinoma Microenvironment through Complement System Activation and Immune Infiltrate Modulation. Int J Mol Sci. 2023; 24(5). PMC: 10003656. DOI: 10.3390/ijms24054814. View

Xu W, Atkins M, Mcdermott D . Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020; 17(3):137-150. DOI: 10.1038/s41585-020-0282-3. View

Vuong L, Kotecha R, Voss M, Hakimi A . Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2019; 9(10):1349-1357. PMC: 6774890. DOI: 10.1158/2159-8290.CD-19-0499. View

Lucarelli G, Rutigliano M, Sallustio F, Ribatti D, Giglio A, Lepore Signorile M . Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging (Albany NY). 2018; 10(12):3957-3985. PMC: 6326659. DOI: 10.18632/aging.101685. View

Ville S, Poirier N, Blancho G, Vanhove B . Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?. Front Immunol. 2015; 6:411. PMC: 4532816. DOI: 10.3389/fimmu.2015.00411. View

10.

Bedke J, Albiges L, Capitanio U, Giles R, Hora M, Lam T . Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol. 2020; 79(3):339-342. DOI: 10.1016/j.eururo.2020.12.005. View

11.

Bombelli S, Torsello B, De Marco S, Lucarelli G, Cifola I, Grasselli C . 36-kDa Annexin A3 Isoform Negatively Modulates Lipid Storage in Clear Cell Renal Cell Carcinoma Cells. Am J Pathol. 2020; 190(11):2317-2326. DOI: 10.1016/j.ajpath.2020.08.008. View

12.

Beatty G, Gladney W . Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2014; 21(4):687-92. PMC: 4334715. DOI: 10.1158/1078-0432.CCR-14-1860. View

13.

Zheng P, Zhou C, Ding Y, Duan S . Disulfidptosis: a new target for metabolic cancer therapy. J Exp Clin Cancer Res. 2023; 42(1):103. PMC: 10134647. DOI: 10.1186/s13046-023-02675-4. View

14.

Stamm H, Oliveira-Ferrer L, Grossjohann E, Muschhammer J, Thaden V, Brauneck F . Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. Oncoimmunology. 2019; 8(12):e1674605. PMC: 6844319. DOI: 10.1080/2162402X.2019.1674605. View

15.

Miao D, Margolis C, Gao W, Voss M, Li W, Martini D . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377):801-806. PMC: 6035749. DOI: 10.1126/science.aan5951. View

16.

Mori K, Mostafaei H, Miura N, Karakiewicz P, Luzzago S, Schmidinger M . Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunol Immunother. 2020; 70(2):265-273. PMC: 7889529. DOI: 10.1007/s00262-020-02684-8. View

17.

Leitner J, Klauser C, Pickl W, Stockl J, Majdic O, Bardet A . B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol. 2009; 39(7):1754-64. PMC: 2978551. DOI: 10.1002/eji.200839028. View

18.

Tamma R, Rutigliano M, Lucarelli G, Annese T, Ruggieri S, Cascardi E . Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. Urol Oncol. 2019; 37(6):355.e11-355.e19. DOI: 10.1016/j.urolonc.2019.01.025. View

19.

Croft M, So T, Duan W, Soroosh P . The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009; 229(1):173-91. PMC: 2729757. DOI: 10.1111/j.1600-065X.2009.00766.x. View

20.

Huang K, Chiang S, Chen T, Chen W, Yang P, Ke T . Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy. Sci Rep. 2020; 10(1):22330. PMC: 7749140. DOI: 10.1038/s41598-020-79419-3. View